Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology.
Level 5 - mechanism / opinion, no new human data
Animal research (5xfAD mouse model)
PubMed 26921617 · doi:10.1093/brain/aww016
What was done
Ten-month-old 5xfAD transgenic Alzheimer's disease model mice were treated for 1 month with a selective colony-stimulating factor 1 receptor (CSF1R) inhibitor to pharmacologically eliminate microglia. The authors evaluated the effects of microglial depletion on amyloid-β levels, plaque load, dendritic spine loss, neuronal loss, neuroinflammation, and contextual memory via behavioural testing.
What was found
CSF1R inhibition resulted in the elimination of ~80% of microglia. This depletion did not alter amyloid-β levels or plaque load. However, microglial elimination reduced overall neuroinflammation, rescued dendritic spine loss, prevented neuronal loss, and improved contextual memory in 5xfAD mice. No other numerical values or statistical metrics were reported in the abstract.
Why it matters
This study demonstrates in a mouse model that microglia directly contribute to neuronal loss and cognitive deficits independently of amyloid plaque clearance or accumulation, identifying microglial survival pathways as a potential target to decouple neurodegeneration from amyloid pathology.
Limits
The study was conducted entirely in transgenic mice (5xfAD), which may not translate to human Alzheimer's disease. The abstract does not report the sample size (n) or exact quantitative effect sizes and confidence intervals. Potential off-target effects and long-term consequences of widespread microglial ablation were not described.
Cited by
- supports In rodent models of Alzheimer's disease, microglial activity is required for beta-amyloid-mediated synapse loss and neuropathology.